

SECURITIES AND EXCHANGE COMMISSION  
Washington, DC 20549

FORM 10-Q

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D)  
OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 1996

Commission file number 0-26224

INTEGRA LIFESCIENCES CORPORATION

-----  
(Exact name of registrant as specified in its charter)

Delaware

51-0317849

-----  
(State or other jurisdiction of  
incorporation or organization)

-----  
(I.R.S. Employer  
Identification No.)

105 Morgan Lane  
Plainsboro, New Jersey

08536

-----  
(Address of principal executive offices)

-----  
(Zip code)

(609) 275-0500

-----  
(Registrant's telephone number, including area code)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

[x] - Yes                      [ ] - No

As of November 10, 1996, the registrant had outstanding 28,551,315 shares of Common Stock, \$.01 par value.

INTEGRA LIFESCIENCES CORPORATION

INDEX

	Page Number
	-----
PART I. FINANCIAL INFORMATION	
Item 1. Financial Statements	
Condensed Consolidated Balance Sheets as of September 30, 1996 and December 31, 1995 (Unaudited)	3
Condensed Consolidated Statements of Operations for the three and nine months ended September 30, 1996 and 1995 (Unaudited)	4
Condensed Consolidated Statements of Cash Flows for the nine months ended September 30, 1996 and 1995 (Unaudited)	5
Notes to Unaudited Condensed Consolidated Financial Statements	6
Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations	7
PART II. OTHER INFORMATION	
Item 6. Exhibits and Reports on Form 8-K	11
SIGNATURES	12
Exhibits	13

PART I. FINANCIAL INFORMATION

Item 1. Financial Statements

INTEGRA LIFESCIENCES CORPORATION AND SUBSIDIARIES  
CONDENSED CONSOLIDATED BALANCE SHEETS  
(UNAUDITED)

	September 30, 1996	December 31, 1995
	-----	-----
<b>ASSETS</b>		
Current Assets:		
Cash and cash equivalents.....	\$ 8,037,079	\$ 4,512,434
Short-term investments.....	24,265,905	1,197,812
Accounts receivable, net.....	2,174,144	1,768,099
Inventories.....	3,059,632	1,372,313
Prepaid expenses and other current assets.....	481,179	468,547
	-----	-----
Total current assets.....	38,017,939	9,319,205
Property and equipment, net.....	8,836,013	9,605,796
Investments.....	4,006,280	--
Intangibles and other assets.....	79,065	452,719
	-----	-----
Total assets.....	\$ 50,939,297	\$ 19,377,720
	=====	=====
<b>LIABILITIES AND STOCKHOLDERS' EQUITY</b>		
Current Liabilities:		
Accounts payable, trade.....	\$ 292,544	\$ 321,304
Accrued expenses.....	1,739,164	1,261,771
Deferred revenue.....	10,650	10,650
Other current liabilities.....	129,731	148,173
Short-term debt-related party.....	--	10,314
Accrual for plant closing.....	--	90,914
	-----	-----
Total current liabilities.....	2,172,089	1,843,126
Other liabilities.....	133,468	107,908
	-----	-----
Total liabilities.....	2,305,557	1,951,034
	-----	-----
Commitments and contingencies		
Stockholders' Equity:		
Preferred stock, \$.01 par value (15,000,000 authorized shares; no shares issued or out- standing).....	--	--
Common stock, \$.01 par value (60,000,000 authorized shares; 28,551,315 and 23,493,916 issued and outstanding at September 30, 1996 and December 31, 1995, respectively).....	285,513	234,939
Additional paid-in capital.....	105,092,464	68,730,310
Notes receivable - related parties.....	(34,875)	(84,875)
Unrealized losses on investments.....	(72,243)	-
Accumulated deficit.....	(56,637,119)	(51,453,688)
	-----	-----
Total stockholders' equity.....	48,633,740	17,426,686
	-----	-----
Total liabilities and stockholders' equity.....	\$ 50,939,297	\$ 19,377,720
	=====	=====

The accompanying notes are an integral part  
of the condensed consolidated financial statements

INTEGRA LIFESCIENCES CORPORATION AND SUBSIDIARIES  
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS  
(UNAUDITED)

	Three Months Ended September 30,		Nine Months Ended September 30,	
	1996	1995	1996	1995
<b>REVENUE</b>				
Product sales.....	\$ 2,590,560	\$ 1,764,278	\$ 8,132,165	\$ 5,814,262
Research grants.....	176,447	219,840	609,982	739,853
Product license fees.....	--	500,000	500,000	500,000
Royalties.....	66,416	43,975	204,409	164,332
Contract product development.....	42,270	25,350	76,136	25,350
<b>Total revenue.....</b>	<b>2,875,693</b>	<b>2,553,443</b>	<b>9,522,692</b>	<b>7,243,797</b>
<b>COSTS AND EXPENSES</b>				
Cost of product sales.....	1,574,780	833,831	4,461,665	2,854,785
Research and development.....	1,591,424	1,556,534	4,814,159	3,590,639
Selling, general and administrative.....	2,349,426	1,596,639	6,873,956	4,407,458
Acquired in-process research and development.....	--	19,592,567	--	19,592,567
<b>Total costs and expenses.....</b>	<b>5,515,630</b>	<b>23,579,571</b>	<b>16,149,780</b>	<b>30,445,449</b>
Operating income (loss).....	(2,639,937)	(21,026,128)	(6,627,088)	(23,201,652)
Interest income.....	490,159	94,705	1,331,684	175,090
Interest expense - related party.....	--	(60,008)	(126)	(187,591)
Loss on sale of investments.....	--	--	(26,176)	--
Gain on sale of assets.....	72,736	--	138,275	5,387
<b>Net income (loss).....</b>	<b>\$ (2,077,042)</b>	<b>\$ (20,991,431)</b>	<b>\$ (5,183,431)</b>	<b>\$ (23,208,766)</b>
<b>Net income (loss) per share.....</b>	<b>\$ (0.07)</b>	<b>\$ (0.97)</b>	<b>\$ (0.19)</b>	<b>\$ (1.15)</b>
Weighted average number of common and common equivalent shares outstanding.....	28,535,093	21,694,627	27,966,990	20,257,688

The accompany notes are an integral part  
of the condensed consolidated financial statements

INTEGRA LIFESCIENCES CORPORATION AND SUBSIDIARIES  
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS  
(UNAUDITED)

	Nine Months Ended September 30,	
	1996	1995
<b>OPERATING ACTIVITIES:</b>		
Net loss.....	\$ (5,183,431)	\$ (23,208,766)
Adjustments to reconcile net income (loss) to net cash used in operating activities:		
Depreciation and amortization.....	1,554,084	849,970
Gain on sale of assets.....	(119,258)	(5,387)
Loss on sale of investments.....	26,176	--
Amortization of discount and interest on investments.....	(780,600)	(4,197)
Common stock issued and stock options vested for services rendered.....	56,404	70,000
Acquired in-process research and development.....	--	19,592,567
Deferred revenue.....	--	(350,000)
Changes in assets and liabilities:		
Accounts receivable.....	(406,045)	(250,826)
Inventories.....	(1,687,319)	(429,475)
Prepays and other current assets.....	(12,633)	(14,833)
Non-current assets.....	141,479	(19,875)
Accounts payable, accrued expenses and other liabilities..	539,441	(625,903)
	(5,871,702)	(4,396,722)
Net cash used in operating activities.....		
<b>INVESTING ACTIVITIES:</b>		
Cash acquired in business acquisition.....	--	13,116,670
Proceeds from sale of assets.....	301,389	12,628
Payments of acquired bankruptcy claims and acquisition costs....	(10,409)	(2,085,318)
Purchases of investments.....	(39,530,332)	(1,176,844)
Proceeds from the sales/maturities of investments.....	13,138,142	-
Purchases of property and equipment.....	(9,889,348)	(2,418,126)
	(27,090,144)	7,449,010
Net cash used in investing activities.....		
<b>FINANCING ACTIVITIES:</b>		
Principal payment on notes payable.....	--	(4,000)
Payments of long-term debt.....	(10,314)	(2,177,578)
Principal payment on notes receivable - related parties.....	50,000	-
Proceeds from long-term debt.....	--	1,937,591
Proceeds from exercised stock options.....	785,343	54,855
Proceeds from sale of common stock.....	35,661,462	1,000,001
	36,486,491	810,869
Net cash provided by financing activities.....		
Net (decrease) increase in cash and cash equivalents.....	3,524,645	3,863,157
Cash and cash equivalents at beginning of period.....	4,512,434	3,331,445
	\$ 8,037,079	\$ 7,194,602
	=====	=====
<b>Supplemental disclosure of non-cash investing and financing activities:</b>		
Debt to equity conversion.....	--	\$ 1,500,005
Common stock issued in business acquisition.....	--	30,912,877

The accompanying notes are an integral part  
of the condensed consolidated financial statements

INTEGRA LIFESCIENCES CORPORATION AND SUBSIDIARIES  
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

1. In the opinion of management, the September 30 unaudited condensed consolidated financial statements contain all adjustments (consisting only of normal recurring accruals) which the Company considers necessary for a fair presentation of the financial position and results of operations of the Company. Operating results for the interim periods ended September 30, 1996 are not necessarily indicative of the results to be expected for the entire year. Certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles have been condensed or omitted. The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, including disclosures of contingent assets and liabilities, and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ from those estimates. These unaudited condensed consolidated financial statements should be read in conjunction with the Company's consolidated financial statements for the year ended December 31, 1995 included in the Company's Annual Report on Form 10-K.
2. The Company's current investment policy is to invest available cash balances in high quality debt securities with maturities not to exceed 18 months. As of September 30, 1996, the Company's marketable securities, which are all classified as available-for-sale, are comprised of the following:

	Amortized Cost	Unrealized Losses	Fair Value
	-----	-----	-----
U.S. Government securities.....	\$ 2,054,801	\$ (6,896)	\$ 2,047,905
U.S. Government agency securities.....	26,289,627	(65,346)	26,224,281
	-----	-----	-----
Total investments.....	28,344,428	(72,242)	28,272,186
Short-term portion of investments.....	\$ 24,344,428	\$ (78,522)	\$ 24,265,906
	=====	=====	=====
Long-term portion of investments.....	\$ 4,000,000	\$ 6,280	\$ 4,006,280
	=====	=====	=====

All long-term investments are securities with call options within one year.

3. Inventories consist of the following:

	September 30, 1996	December 31, 1995
	-----	-----
Finished goods.....	\$ 889,469	\$ 480,343
Work-in-process.....	1,750,730	516,840
Raw materials.....	419,433	375,130
	-----	-----
	\$ 3,059,632	\$ 1,372,313
	=====	=====

4. On February 1, 1996, the Company completed the issuance of 4,671,250 shares of common stock through a public offering resulting in net proceeds of approximately \$35.6 million.
5. Net loss per share is based on the weighted average number of common and common equivalent shares outstanding during the periods. Options and warrants have been excluded in the calculation of common and common equivalent shares for the periods they are antidilutive.

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations

The following discussion contains trend information and other forward-looking statements related to the future use of INTEGRA(Trademark) Artificial Skin and anticipated expenditure levels and are made pursuant to the safe harbor provisions of the Securities Litigation Reform Act of 1995. Such statements involve risks and uncertainties which may cause results to differ materially from those set forth in these statements. In addition, the economic, competitive, governmental, technological and other factors identified in the Company's Annual Report on Form 10-K filed with the Securities and Exchange Commission could affect such results.

General

The Company is engaged in the manufacturing and sale of collagen and other biomaterials-based medical products and related product development, and in the development of collagen and other biomaterials-based regenerative medicine technologies. The Company's business strategy has been to selectively acquire a number of synergistic biomaterials and extracellular matrix-based technologies. The Company acquired ABS LifeSciences, Inc. in November 1990, Colla-Tec, Inc. in September 1991, Vitaphore Corporation in April 1993, Biomat Corporation in September 1993, another company's interest in a joint venture with Vitaphore in December 1993 and Telios Pharmaceuticals, Inc. ("Telios") in August 1995. As a result of the Company's acquisition of Telios, the consolidated financial results for the periods presented below may not be directly comparable.

Results of Operations

Three Months Ended September 30, 1996 Compared to Three Months Ended September 30, 1995

Total revenues increased to approximately \$2.9 million for the three months ended September 30, 1996 from \$2.6 million for the three months ended September 30, 1995. Increases in product sales, royalty revenue and contract product development revenue were offset by a decrease in product license fees and research grant revenue. Product sales increased to \$2.6 million for the three months ended September 30, 1996 from \$1.8 million for the three months ended September 30, 1995, due primarily to sales of the INTEGRA(Trademark) Artificial Skin product ("INTEGRA(Trademark)"). Sales of INTEGRA(Trademark) for the three months ended September 30, 1996 were \$860,000 compared to \$20,000 in international sales for the three months ended September 30, 1995, which was prior to the U.S. Food and Drug Administration (FDA) approval of the Company's Premarket Approval Application in March 1996. During the three-month period ended September 30, 1996, the Company believes approximately 85 patients were treated with INTEGRA(Trademark). The Company has determined the approximate patient total by reviewing sales information as well as case information supplied by physicians to the extent such information is made available to the Company. The number of patients treated quarterly may not necessarily be comparable to INTEGRA(Trademark) sales due to the timing of orders, the amount of INTEGRA(Trademark) use per patient and customer stocking levels, particularly internationally where the Company sells through distributors. The Company believes that the primary application of INTEGRA(Trademark) has been for patients with severe life-threatening burns, but is aware of its application in reconstructive and wound healing procedures, primarily outside the United States. Factors influencing the use and sale of INTEGRA(Trademark) include physician training prior to product use, the collection of pharma-economic data to address initial product reimbursement issues, additional positive clinical results and the Company's ability to obtain FDA approvals for additional indications.

Product sales of the Company's other medical devices were approximately \$1.7 million for the three month periods ended September 30, 1996 and 1995, with an increase in the Company's dental product line offset by decreases in its ophthalmic and surgical and hemostasis product lines. The dental product line increase came from the Company's BioMend product which commenced market roll-out in August

1995. The Company's ophthalmic product sales decreased because of production difficulties, and surgical and hemostasis product sales decreased largely due to timing differences in orders shipped to contract distributors. The Company is currently evaluating its ophthalmic product line production difficulties which, if not remedied, could continue to affect the Company's future sales. Sales of the Company's other medical devices can vary significantly on a quarter to quarter basis depending on the timing of shipments to contract distributors. Export sales for the three months ended September 30, 1996 increased to \$570,000 from \$300,000 for the three months ended September 30, 1995, and included \$330,000 in INTEGRA(Trademark) sales.

Research grant revenue decreased for the three-month period ended September 30, 1996 compared to the same period in 1995 due to the completion of funding under a Contraceptive Research and Development ("CONRAD") program grant received in 1995. The Company recently received \$570,000 in grant funding under five separate grants, three of which are Phase 1 Small Business Innovative Research grants from the National Institute of Health. The two other grants are a matching State of New Jersey grant in collaboration with Rutgers University and an additional CONRAD reproductive health grant. The Company did not receive any licensing fees during the three-month period ended September 30, 1996 compared to \$500,000 received during the three-month period ended September 30, 1995 when its BioMend(Trademark) product received 510(k) approval. The Company continues to seek research grants, licensing and development funding for several of its technologies. The timing and amount of this funding, if any, can not be predicted.

Cost of product sales increased to approximately \$1.6 million (61% of product sales) for the three months ended September 30, 1996 from \$830,000 (47% of product sales) for the three months ended September 30, 1995. The increase in cost of product sales as a percentage of sales is primarily attributable to \$450,000 in inventory write-offs largely from in-process production difficulties in the Company's ophthalmic product line. Excluding the inventory write-offs, the Company's gross margin for the three months ended September 30, 1996 would have improved compared to the three months ended September 30, 1995 due to increased sales of higher gross margin products, including INTEGRA(Trademark). The Company is currently evaluating the in-process production difficulties in its ophthalmic product line, and any delay in the resolution of these difficulties could continue to negatively impact the Company's gross margin. The Company believes that its current capacity to produce INTEGRA(Trademark) and its other medical device products is sufficient to support significant growth, and the utilization of this capacity will affect its gross margin on product sales.

Research and development expense was approximately \$1.6 million for the three-month periods ended September 30, 1996 and 1995. Research and development expense incurred by the Company's Telios operation increased to \$590,000 for the three months ended September 30, 1996 from \$430,000 for the three months ended September 30, 1995, which included only six weeks of Telios' post-acquisition activity. The Company's research and development efforts involving INTEGRA(Trademark) decreased significantly between the 1995 and 1996 periods as a result of the transfer of the product to manufacturing. Additional increases in other research and development projects partially offset the decrease related to the INTEGRA(Trademark) transfer. These increases included costs associated with the addition of full-time and part-time research and development staff and increased expenditures for outside contract research activities for the Company's regenerative medicine technologies. The Company expects the level of research and development expenditures in 1996 to continue to remain at or exceed 1995 expenditures due to expenditures related to a planned post approval study of INTEGRA(Trademark) and clinical trials for the Company's regenerative and matrix medicine technologies. The amount of resources and the allocation of those resources to fund research and development will vary depending upon a number of factors, including the progress of development of the Company's technologies, changing competitive conditions and determinations with respect to the commercial potential of the Company's technologies.



Selling, general and administrative expense increased to approximately \$2.3 million for the three-month period ended September 30, 1996 from \$1.6 million for the three-month period ended September 30, 1995, due in part to an increase of \$200,000 in general and administrative expense incurred by the Company's Telios operation. A significant portion of Telios' administrative expense is maintaining its intellectual property and for the three-month period ended September 30, 1996 included significant expenditures related to patent infringement litigation. Sales and marketing expenses increased by \$420,000 as a result of the domestic and international market introduction of INTEGRA(Trademark), which included approximately seven domestic and international surgeon training programs during the third quarter of 1996. These costs were partially offset by a decrease in costs resulting from a reduction in the size of the Company's direct sales force for certain medical product lines. The Company is anticipating selling, general and administrative expense to remain higher than 1995 levels due to the ongoing introduction of INTEGRA(Trademark) and Telios' patent infringement litigation.

Nine Months Ended September 30, 1996 Compared to Nine Months Ended September 30, 1995

Total revenues increased to approximately \$9.5 million for the nine months ended September 30, 1996 from \$7.2 million for the nine months ended September 30, 1995. Increases in product sales, royalty revenue and contract product development revenue were offset by a decrease in research grant revenue. Product sales increased to \$8.1 million for the nine months ended September 30, 1996 from \$5.8 million for the nine months ended September 30, 1995, due primarily to \$1.8 million in INTEGRA(Trademark) sales. During the nine-month period ended September 30, 1996, the Company believes approximately 159 patients were treated with INTEGRA(Trademark). The number of patients treated over any given period may not necessarily be comparable to INTEGRA(Trademark) sales due to the factors mentioned previously.

Product sales of the Company's other medical devices increased to approximately \$6.3 million for the nine months ended September 30, 1996 from \$5.8 million for the nine months ended September 30, 1995, with increases in the Company's infection control and dental product lines partially offset by decreases in its wound care, ophthalmic, and surgical and hemostasis product lines. The largest sales increases were in the Company's BioMend and BioPatch products both of which are sold under private label distribution contracts. The surgical and hemostasis product sales decreased because of lower requirement levels under a private label distribution contract and price decreases in its direct distribution products. The Company has also recently introduced additional surgical and hemostasis product sizes under its direct distribution product lines. The ophthalmic product line decrease was a result of production difficulties experienced during 1996. Export sales for the nine months ended September 30, 1996 increased to \$1.3 million from \$790,000 for the nine months ended September 30, 1995, and included \$620,000 in INTEGRA(Trademark) sales in over ten countries during the 1996 period.

Research grant revenue decreased for the nine-month period ended September 30, 1996 compared to the same period in 1995 due primarily to the completion of funding under a CONRAD Program grant. The increase in contract product development revenue is related to a wound care product development agreement which expired in October 1996.

Cost of product sales increased to approximately \$4.5 million (55% of product sales) for the nine months ended September 30, 1996 from \$2.9 million (49% of product sales) for the nine months ended September 30, 1995. The increase in costs of product sales is attributable to higher product sales, costs associated with scale-up of the INTEGRA(Trademark) manufacturing process during the first quarter of 1996 and inventory write-offs during the third quarter of 1996.

Research and development expense increased to approximately \$4.8 million for the nine-month period ended September 30, 1996 from \$3.6 million for the nine-month period ended September 30, 1995, due primarily to \$1.6 million in research and development expense incurred by the Company's Telios operation. The Company's research and development efforts involving INTEGRA(Trademark) decreased significantly between the 1995 and 1996 periods as a result of the transfer of the product to

manufacturing. Additional increases in other research and development projects partially offset the decrease related to the INTEGRA(Trademark) transfer. These increases included costs associated with the addition of full-time and part-time research and development staff and increased expenditures for outside contract research activities related to the Company's regenerative medicine technologies.

Selling, general and administrative expense increased to approximately \$6.9 million for the nine-month period ended September 30, 1996 from \$4.4 million for the nine-month period ended September 30, 1995, due in part to an increase of \$1.3 million in general and administrative expense incurred by the Company's Telios operation. Sales and marketing expenses increased by \$1.1 million as a result of the domestic and international market introduction of INTEGRA(Trademark), which included approximately 21 domestic and international surgeon training programs during the first nine months of 1996. These costs were partially offset by a decrease in costs resulting from a reduction in the size of the Company's direct sales force for certain medical product lines. Additional smaller increases in expenses were incurred in administrative and regulatory areas related to the expansion of the Company's business and public company reporting requirements.

#### Liquidity and Capital Resources

At September 30, 1996, the Company had cash and cash equivalents of approximately \$8.0 million, short-term and long-term investments totaling \$28.3 million and no long-term debt. The Company's principal sources of liquidity during the nine-month period ended September 30, 1996 were the receipt of \$35.6

million in proceeds from an underwritten public offering of the Company's common stock, \$790,000 from the exercise of stock options under the Company's stock option plans and \$300,000 from the sale of fixed assets. The principal uses of funds during the period were \$5.9 million for operations and \$990,000 in purchases of property and equipment. As a result of the public offering, the Company's revolving line of credit terminated in accordance with its terms.

The Company anticipates that it will continue to use its liquid assets to fund operations until sufficient revenues can be generated through product sales and collaborative arrangements. The Company also expects that it will need to fund additional growth in its accounts receivable and inventory in conjunction with INTEGRA(Trademark). There can be no assurance that the Company will be able to generate sufficient revenues to obtain profitability.

PART II. OTHER INFORMATION

Item 6. Exhibits and Reports on Form 8-K

(a) Exhibits

11	Statement re Computation of Per Share Amounts
27	Financial Data Schedule

(b) Reports on Form 8-K

None

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

INTEGRA LIFESCIENCES CORPORATION

Date: November 14, 1996

/s/ Richard E. Caruso

-----  
Richard E. Caruso, Ph.D.  
Chairman, President and Chief Executive Officer

Date: November 14, 1996

/s/ John R. Emery

-----  
John R. Emery  
Senior Vice President, Operations and Finance

## Statement of Computation of Per Share Amounts

	Three Months Ended September 30,		Nine Months Ended September 30,	
	1996	1995	1996	1995
<b>Primary:</b>				
Net loss for the period.....	\$(2,077,042)	\$(20,991,431)	\$(5,183,431)	\$(23,208,766)
Weighted average number of shares of common stock outstanding.....	28,535,093	21,694,627	27,966,990	20,257,688
Shares issuable upon exercise of outstanding options and warrants.....	--	--	--	--
Shares assumed to be acquired in accordance with the treasury stock method.....	--	--	--	--
Shares used in computing per share loss.....	28,535,093	21,694,627	27,966,990	20,257,688
Net loss per share.....	\$ (0.07)	\$ (0.97)	\$ (0.19)	\$ (1.15)
<b>Fully Diluted:</b>				
Net loss for the period.....	\$(2,077,042)	\$(20,991,431)	\$(5,183,431)	\$(23,208,766)
Weighted average number of shares of common stock outstanding.....	28,535,093	21,694,627	27,966,990	20,257,688
Shares issuable upon exercise of outstanding options and warrants.....	1,366,996	3,227,241	3,371,462	3,366,863
Shares assumed to be acquired in accordance with the treasury stock method.....	(57,319)	(1,408,367)	(1,549,637)	(1,467,270)
Shares used in computing per share loss.....	29,844,770	23,513,501	29,788,815	22,157,281
Net loss per share.....	\$ (0.07)	\$ (0.89)	\$ (0.17)	\$ (1.05)

9-MOS  
DEC-31-1996  
JAN-01-1996  
SEP-30-1996  
8,037,079  
28,272,185  
2,174,144  
0  
3,059,632  
38,017,939  
12,651,020  
3,815,007  
50,939,297  
2,172,089  
0  
0  
285,513  
48,348,227  
50,939,297  
8,132,165  
9,522,692  
4,461,665  
0  
0  
126  
(5,183,431)  
0  
(5,183,431)  
0  
0  
(5,183,431)  
(.19)  
(.19)